Browse > Article
http://dx.doi.org/10.5230/jgc.2022.22.e2

Bleeding After Gastric Endoscopic Submucosal Dissection Focused on Management of Xa Inhibitors  

Ono, Shoko (Division of Endoscopy, Hokkaido University Hospital)
Ieko, Masahiro (Department of Clinical Laboratory, Iwate Prefectural Chubu Hospital)
Tanaka, Ikko (Department of Gastroenterology and Hepatology, Graduate School of Medicine and Faculty of Medicine Hokkaido University)
Shimoda, Yoshihiko (Department of Gastroenterology and Hepatology, Graduate School of Medicine and Faculty of Medicine Hokkaido University)
Ono, Masayoshi (Department of Gastroenterology and Hepatology, Graduate School of Medicine and Faculty of Medicine Hokkaido University)
Yamamoto, Keiko (Department of Gastroenterology and Hepatology, Graduate School of Medicine and Faculty of Medicine Hokkaido University)
Sakamoto, Naoya (Department of Gastroenterology and Hepatology, Graduate School of Medicine and Faculty of Medicine Hokkaido University)
Publication Information
Journal of Gastric Cancer / v.22, no.1, 2022 , pp. 47-55 More about this Journal
Abstract
Purpose: The use of direct oral Xa inhibitors (DXaIs) to prevent venothrombotic events is increasing. However, gastrointestinal bleeding, including that related to endoscopic resection, is a concern. In this study, we evaluated bleeding and coagulation times during the perioperative period of gastric endoscopic submucosal dissection (ESD). Materials and Methods: Patients who consecutively underwent gastric ESD from August 2016 to December 2018 were analyzed. Bleeding rates were compared among the 3 groups (antiplatelet, DXaIs, and control). DXaI administration was discontinued on the day of the procedure. Prothrombin time (PT), activated partial thromboplastin time, and the ratio of inhibited thrombin generation (RITG), which was based on dilute PT, were determined before and after ESD. Results: During the study period, 265 gastric ESDs were performed in 239 patients, where 23 and 50 patients received DXaIs and antiplatelets, respectively. Delayed bleeding occurred in 17 patients (7.4%) and 21 lesions (7.1%). The bleeding rate in the DXaI group was significantly higher than that in the other groups (30.4%, P<0.01), and the adjusted odds ratio of bleeding was 5.7 (95% confidence interval, 1.4-23.7; P=0.016). In patients using DXaIs, there was a significant (P=0.046) difference in the median RITG between bleeding cases (18.6%) and non-bleeding cases (3.8%). Conclusions: A one-day cessation of DXaIs was related to a high incidence of bleeding after gastric ESD, and monitoring of residual coagulation activity at trough levels might enable the predicted risk of delayed bleeding in patients using DXaIs.
Keywords
Gastric cancer; Endoscopic submucosal dissection; Factor Xa inhibitor; Hemorrhage;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Harada H, Nakahara R, Murakami D, Suehiro S, Nagasaka T, Ujihara T, et al. The effect of anticoagulants on delayed bleeding after colorectal endoscopic submucosal dissection. Surg Endosc 2020;34:3330-3337.   DOI
2 Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017;151:127-138.   DOI
3 Veitch AM, Vanbiervliet G, Gershlick AH, Boustiere C, Baglin TP, Smith LA, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy 2016;48:385-402.   DOI
4 Ono H, Yao K, Fujishiro M, Oda I, Nimura S, Yahagi N, et al. Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer. Dig Endosc 2016;28:3-15.   DOI
5 Choi J, Cho SJ, Na SH, Lee A, Kim JL, Chung H, et al. Use of direct oral anticoagulants does not significantly increase delayed bleeding after endoscopic submucosal dissection for early gastric neoplasms. Sci Rep 2021;11:9399.   DOI
6 Ono S, Ono M, Nakagawa M, Shimizu Y, Kato M, Sakamoto N. Delayed bleeding and hemorrhage of mucosal defects after gastric endoscopic submucosal dissection on second-look endoscopy. Gastric Cancer 2016;19:561-567.   DOI
7 Ono S, Ishikawa M, Matsuda K, Tsuda M, Yamamoto K, Shimizu Y, et al. Clinical impact of the perioperative management of oral anticoagulants in bleeding after colonic endoscopic mucosal resection. BMC Gastroenterol 2019;19:206.   DOI
8 Matsumoto M, Mabe K, Tsuda M, Ono M, Omori S, Takahashi M, et al. Multicenter study on hemorrhagic risk of heparin bridging therapy for periendoscopic thromboprophylaxis. BMC Gastroenterol 2015;15:89.   DOI
9 Chan FKL, Goh KL, Reddy N, Fujimoto K, Ho KY, Hokimoto S, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines. Gut 2018;67:405-417.   DOI
10 Yoshio T, Tomida H, Iwasaki R, Horiuchi Y, Omae M, Ishiyama A, et al. Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection. Dig Endosc 2017;29:686-694.   DOI
11 Pratt J, Crispin P. Screening test for direct oral anticoagulants with the dilute Russell viper venom time. Eur J Haematol 2018;100:567-574.   DOI
12 Suzuki S, Otsuka T, Sagara K, Kano H, Matsuno S, Kato Y, et al. Rivaroxaban in clinical practice for atrial fibrillation with special reference to prothrombin time. Circ J 2014;78:763-766.   DOI
13 Radaelli F, Fuccio L, Paggi S, Hassan C, Repici A, Rondonotti E, et al. Periendoscopic management of direct oral anticoagulants: a prospective cohort study. Gut 2019;68:969-976.   DOI
14 Toya Y, Endo M, Oizumi T, Akasaka R, Yanai S, Kawasaki K, et al. Risk factors for post-gastric endoscopic submucosal dissection bleeding with a special emphasis on anticoagulant therapy. Dig Dis Sci 2020;65:557-564.   DOI
15 Park SH, Seo YH, Park PW, Kim KH, Seo JY, Lee HT, et al. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: experience at a single institution. J Clin Lab Anal 2019;33:e22869.   DOI
16 Ieko M, Ohmura K, Naito S, Yoshida M, Sakuma I, Ikeda K, et al. Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: results of multicenter study in Japan. Thromb Res 2020;195:158-164.   DOI
17 Oda I, Gotoda T, Hamanaka H, Eguchi T, Saito Y, Matsuda T, et al. Endoscopic submucosal dissection for early gastric cancer: technical feasibility, operation time and complications from a large consecutive series. Dig Endosc 2005;17:54-58.   DOI
18 Koh R, Hirasawa K, Yahara S, Oka H, Sugimori K, Morimoto M, et al. Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms. Gastrointest Endosc 2013;78:476-483.   DOI
19 Hasuike N, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H, et al. A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer 2018;21:114-123.   DOI
20 Ueki N, Futagami S, Akimoto T, Maruki Y, Yamawaki H, Kodaka Y, et al. Effect of antithrombotic therapy and long endoscopic submucosal dissection procedure time on early and delayed postoperative bleeding. Digestion 2017;96:21-28.   DOI
21 ASGE Standards of Practice Committee, Acosta RD, Abraham NS, Chandrasekhara V, Chathadi KV, Early DS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016;83:3-16.   DOI
22 Kato M, Uedo N, Hokimoto S, Ieko M, Higuchi K, Murakami K, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment: 2017 appendix on anticoagulants including direct oral anticoagulants. Dig Endosc 2018;30:433-440.   DOI
23 Nagata N, Yasunaga H, Matsui H, Fushimi K, Watanabe K, Akiyama J, et al. Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis. Gut 2018;67:1805-1812.   DOI
24 Fujimoto K, Fujishiro M, Kato M, Higuchi K, Iwakiri R, Sakamoto C, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc 2014;26:1-14.
25 Kubo K, Kato M, Mabe K, Harada N, Iboshi Y, Kagaya T, et al. Risk factors for delayed bleeding after therapeutic gastrointestinal endoscopy in patients receiving oral anticoagulants: a multicenter retrospective study. Digestion 2021;102:161-169.   DOI
26 Yasuda R, Yoshida N, Murakami T, Hirose R, Inoue K, Dohi O, et al. Multicenter study of the hemorrhage risk after endoscopic mucosal resection associated with direct oral anticoagulants. Gastroenterol Res Pract 2019;2019:5743561.
27 Sanomura Y, Oka S, Tanaka S, Yorita N, Kuroki K, Kurihara M, et al. Taking warfarin with heparin replacement and direct oral anticoagulant is a risk factor for bleeding after endoscopic submucosal dissection for early gastric cancer. Digestion 2018;97:240-249.   DOI
28 Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc 2013;78:227-239.   DOI
29 Jaruvongvanich V, Assavapongpaiboon B, Wijarnpreecha K, Ungprasert P. Heparin-bridging therapy and risk of post-polypectomy bleeding: meta-analysis of data reported by Japanese colonoscopists. Dig Endosc 2017;29:743-748.   DOI
30 Saito H, Igarashi K, Hirasawa D, Okuzono T, Suzuki K, Abe Y, et al. The risks and characteristics of the delayed bleeding after endoscopic submucosal dissection for early gastric carcinoma in cases with anticoagulants. Scand J Gastroenterol 2020;55:1253-1260.   DOI
31 Nagakari K, Emmi M, Iba T. Prothrombin time tests for the monitoring of direct oral anticoagulants and their evaluation as indicators of the reversal effect. Clin Appl Thromb Hemost 2017;23:677-684.   DOI
32 Hinder M, Frick A, Jordaan P, Hesse G, Gebauer A, Maas J, et al. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease. Clin Pharmacol Ther 2006;80:691-702.   DOI